The Transgender Movement Is Collapsing in England after the Cass Review

According to Maya Forstater, who was fired for opposing gender ideology, won a wrongful dismissal lawsuit, and founded the campaign organization Sex Matters, these coming changes are a “major step” towards walking back NHS England’s “capitulation to the demands of gender extremists, which has damaged policies and practices, created widespread confusion, and harmed patient care.” 

Is it possible that the transgender tide might go out as swiftly as it came in? 

The impact of the Cass Review has been international, but the response has been mixed. The Netherlands rejected “self-identification” by a wide margin, but Sweden and Germany approved it. The Canadian establishment claimed the findings were “transphobic,” and the American LGBT activists similarly ignored these findings. Some people won’t wake up until the lawsuits are served. 

In the U.K., however, the Cass Review appears to be a tipping point. Scotland’s “gender clinics” have paused the prescription of puberty blockers (which England’s National Health Service has banned entirely outside of clinical trials). The NHS has also announced that in the wake of the Cass Review, an independent review of adult “gender clinics” will also be conducted (although Hilary Cass, who currently cannot use public transit due to security concerns, will not be spearheading it). 

Indeed, the NHS is not wasting any time in reversing the changes that have crept in over the past decade. Health Secretary Victoria Atkins is scheduled to announce changes to the NHS constitution on patients’ rights this week with an eight-week consultation period, according to the Telegraph. These changes, it appears, will actually be a reversion to the norm, with terms such as “chestfeeding” and “people with ovaries” banned in favor of the sex-specific terms previously used.  

As I reported in this space over the past several years, references to women had slowly but steadily been removed from NHS websites and medical documents, even on female-specific subjects such as cervical and ovarian cancer and menopause.  

Read More

Previous ArticleNext Article